American Asset Management Inc. boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,318 shares of the medical instruments supplier’s stock after buying an additional 2 shares during the period. American Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $242,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in BDX. Norges Bank purchased a new stake in Becton, Dickinson and Company during the fourth quarter valued at about $253,005,000. Asset Management One Co. Ltd. raised its stake in shares of Becton, Dickinson and Company by 1,331.7% in the fourth quarter. Asset Management One Co. Ltd. now owns 373,412 shares of the medical instruments supplier’s stock worth $61,838,000 after buying an additional 347,331 shares during the last quarter. State Street Corp raised its stake in shares of Becton, Dickinson and Company by 3.0% in the fourth quarter. State Street Corp now owns 12,030,526 shares of the medical instruments supplier’s stock worth $1,991,654,000 after buying an additional 345,367 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $55,766,000. Finally, Janus Capital Management LLC raised its stake in shares of Becton, Dickinson and Company by 29.2% in the fourth quarter. Janus Capital Management LLC now owns 1,460,176 shares of the medical instruments supplier’s stock worth $241,732,000 after buying an additional 329,670 shares during the last quarter. Hedge funds and other institutional investors own 75.41% of the company’s stock.

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson and Company (NYSE:BDX) opened at 193.48 on Tuesday. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $194.11. The stock has a market cap of $41.27 billion, a P/E ratio of 32.13 and a beta of 1.04. The firm’s 50-day moving average is $187.51 and its 200-day moving average is $179.76.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.23 by $0.07. The business had revenue of $2.97 billion for the quarter, compared to analysts’ expectations of $2.92 billion. Becton, Dickinson and Company had a net margin of 10.67% and a return on equity of 25.37%. The business’s quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.18 earnings per share. Equities research analysts predict that Becton, Dickinson and Company will post $9.44 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 30th. Stockholders of record on Friday, June 9th will be given a dividend of $0.73 per share. The ex-dividend date of this dividend is Wednesday, June 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.51%. Becton, Dickinson and Company’s dividend payout ratio is presently 48.26%.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.dailypolitical.com/2017/06/20/american-asset-management-inc-acquires-2-shares-of-becton-dickinson-and-company-bdx.html.

A number of equities research analysts recently weighed in on BDX shares. Jefferies Group LLC reiterated a “buy” rating and set a $200.00 price objective on shares of Becton, Dickinson and Company in a report on Wednesday, March 29th. Zacks Investment Research upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating and set a $206.00 price objective for the company in a report on Tuesday, April 11th. Royal Bank Of Canada reiterated a “hold” rating and set a $177.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, April 13th. Finally, Evercore ISI upgraded shares of Becton, Dickinson and Company from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $186.00 to $200.00 in a report on Monday, April 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. Becton, Dickinson and Company presently has an average rating of “Buy” and a consensus target price of $186.09.

In other news, VP Jeffrey S. Sherman sold 28,765 shares of the stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the sale, the vice president now owns 70,821 shares of the company’s stock, valued at $13,171,289.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.